Table 1 Characteristics of the cancer sera and types of cell lines cultured
From: Transfer of malignant trait to immortalized human cells following exposure to human cancer serum
Cells/Conditions | Animals with tumora | Latency (days) | Tumor volume (cm3) |
|---|---|---|---|
HEK293/Control human serum | 0/6 | 30 | -- |
HEK293/Case18 (PcC/LM) | 3/3 | 30 | 0.930 +/− 0.130 |
HEK293 /Case21 (Leiomyosarcoma) | 3/3 | 30 | 0.610 +/− 0.122 |
HEK293/Case9 (CRC/LM) | 3/3 | 30 | 0.241 +/− 0.090 |
HEK293/Case14 (BC/LM) | 3/3 | 30 | 1.064 +/− 0.073 |
HEK293/Control medium | 0/3 | 30 | -- |
HEK293/CM-Colo320 | 3/3 | 30 | 0.288 +/− 0.017 |
hESC WA01/Control human serum | 0/2 | 185 | -- |
hESC WA01/Case23 (CC/LM) | 0/2 | 185 | -- |
hESC WA01/Control human serum | 0/5 | 210 | -- |
hESC WA01/Case4 (GC/Peritoneal seeding) | 0/5 | 210 | -- |
hESC WA01/Control human serum | 0/5 | 120 | -- |
hESC WA01/Case8 (CC/LM) | 0/6 | 120 | -- |
hESC WA01/Control human serum | 0/4 | 155 | -- |
hESC WA01/Case19 (GC/LM) | 0/7 | 155 | -- |
hESC WA01/Control human serum | 0/2 | 119 | -- |
hESC WA01/Case7 (Neuroendocrine) | 0/3 | 119 | -- |
hESC WA01/Control human serum | 0/2 | 104 | -- |
hESC WA01/Case10 (BC/BM + lM) | 0/2 | 104 | -- |
hESC WA01/Control human serum | 0/3 | 60 | -- |
hESC WA01/Case13 (CRC/LM + BM) | 0/3 | 60 | -- |
hALF/Control human serum | 0/2 | 70 | -- |
hALF/Case16 (CRC/LM) | 0/2 | 70 | -- |
hMSC /Control human serum | 0/2 | 98 | -- |
hMSC /Case20 (CC/LM) | 0/2 | 98 | -- |
hMSC /Case22 (BrC/LM + lM) | 0/2 | 98 | -- |